Skip to content

Tag Archives: therapeutic

A high proportion of users of low-threshold facilities with needle exchange programmes in Switzerland are currently on methadone treatment:…

Abstract: Background: Increasingly, patients receiving methadone treatment are found in low threshold facilities (LTF), which provide needle exchange programmes in Switzerland. This paper identifies the characteristics of LTF attendees receiving methadone treatment (MT) compared with other LTF attendees (non-MT).Methods: A national cross-sectional survey was conducted in 2006 over five consecutive days in all LTF (n=25). Attendees were given an anonymous questionnaire, collecting information on socio-demographic indicators, drug consumption, injection, methadone treatment, and self-reported HIV and HCV status.

Employment-Based Reinforcement of Adherence to Depot Naltrexone in Unemployed Opioid-Dependent Adults: A Randomized Controlled Trial

Abstract Aims:  Naltrexone can be used to treat opioid dependence, but patients refuse to take it. Extended-release depot formulations may improve adherence, but long-term adherence rates to depot naltrexone are not known.

The expansion of the field of research on ayahuasca: Some reflections about the ayahuasca track at the 2010 MAPS “Psychedelic Science in the 21st…

A recent conference sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) in collaboration with the Heffter Research Institute, the Beckley Foundation and the Council on Spiritual Practices held from April 15th to 18th 2010, in San José, USA () united 90 presenters and 1100 participants with the goal of giving visibility to studies on the therapeutic potentials of psychedelics (psilocybin, MDMA, ibogaine, ayahuasca, etc.) in the treatment of often intractable ailments such as anxiety in terminal cancer patients, cluster headaches, obsessive–compulsive disorders, drug addiction, and post-traumatic stress disorders, as well as the role of these substances in human enhancement and well-being in general. MAPS was chartered in 1986, with the mission to develop cannabis and psychedelics into prescription medicines to treat illnesses, to build a network of clinics where these prescription medicines can be administered, and to provide public education on the harm and benefits of using psychedelics and cannabis.

The expansion of the field of research on ayahuasca: Some reflections about the ayahuasca track at the 2010 MAPS “Psychedelic Science in the…

A recent conference sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) in collaboration with the Heffter Research Institute, the Beckley Foundation and the Council on Spiritual Practices held from April 15th to 18th 2010, in San José, USA () united 90 presenters and 1100 participants with the goal of giving visibility to studies on the therapeutic potentials of psychedelics (psilocybin, MDMA, ibogaine, ayahuasca, etc.) in the treatment of often intractable ailments such as anxiety in terminal cancer patients, cluster headaches, obsessive–compulsive disorders, drug addiction, and post-traumatic stress disorders, as well as the role of these substances in human enhancement and well-being in general. MAPS was chartered in 1986, with the mission to develop cannabi…

The expansion of the field of research on ayahuasca: Some reflections about the ayahuasca track at the 2010 MAPS “Psychedelic Science in the…

A recent conference sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) in collaboration with the Heffter Research Institute, the Beckley Foundation and the Council on Spiritual Practices held from April 15th to 18th 2010, in San José, USA () united 90 presenters and 1100 participants with the goal of giving visibility to studies on the therapeutic potentials of psychedelics (psilocybin, MDMA, ibogaine, ayahuasca, etc.) in the treatment of often intractable ailments such as anxiety in terminal cancer patients, cluster headaches, obsessive–compulsive disorders, drug addiction, and post-traumatic stress disorders, as well as the role of these substances in human enhancement and well-being in general. MAPS was chartered in 1986, with the mission to develop cannabi…

Substance abuser impulsivity decreases with a nine-month stay in a therapeutic community.

Conclusion: Impulsivity decreased in subjects who remained in therapeutic community for nine months although self-reported impulsivity at baseline did not seem to be associated with retention. Scientific Significance: Therapeutic community factors contribute to a decrease in self-reported impulsivity and these factors might be enhanced to increase retention in therapeutic community. PMID: 20014910 [PubMed - in process] (Source: The American Journal of Drug and Alcohol Abuse)

Are the effects of gamma-hydroxybutyrate (GHB) treatment partly physiological in alcohol dependence?

Authors: Ameisen O It has been hypothesized that the therapeutic effects of Gamma-hydroxybutyrate (GHB) in alcohol dependence could be related to ethanol-mimicking action of the drug and that GHB could reduce alcohol craving, intake and withdrawal by acting as a “substitute” of the alcohol in the central nervous system. Nevertheless, alcohol being the strongest trigger of craving and intake, it is difficult to ascribe reduction of craving and intake to ethanol-mimicking activity of GHB

Are the effects of gamma-hydroxybutyrate (GHB) treatment partly physiological in alcohol dependence?

Authors: Ameisen O It has been hypothesized that the therapeutic effects of Gamma-hydroxybutyrate (GHB) in alcohol dependence could be related to ethanol-mimicking action of the drug and that GHB could reduce alcohol craving, intake and withdrawal by acting as a “substitute” of the alcohol in the central nervous system.

Further validity evidence for the dimensions of change in therapeutic community treatment instrument.

Authors: Edelen MO, Miles JN, Osilla KC, Wenzel SL Recent research efforts have focused on assessing the therapeutic community (TC) treatment process. The current article examines the validity of the client self-report Dimensions of Change Instrument (DCI) treatment process measure, by confirming its factor structure and examining each subscale’s relationship with time in treatment, scales from an existing process assessment, and mental and physical health status. Participants were 511 adult and adolescent residential TC clients

Further validity evidence for the dimensions of change in therapeutic community treatment instrument.

Authors: Edelen MO, Miles JN, Osilla KC, Wenzel SL Recent research efforts have focused on assessing the therapeutic community (TC) treatment process. The current article examines the validity of the client self-report Dimensions of Change Instrument (DCI) treatment process measure, by confirming its factor structure and examining each subscale’s relationship with time in treatment, scales from an existing process assessment, and mental and physical health status. Participants were 511 adult and adolescent residential TC clients.